Please enable Javascript
Yvette C. Terrie
Yvette C. Terrie
Yvette C. Terrie
Articles by Yvette C. Terrie
PALMARES-2 Study Highlights Variable Efficacy of CDK4/6 Inhibitors in HER2-Negative Advanced Breast Cancer
Yvette C. Terrie
HR Breast Cancer
|
May 7, 2025
Real-world data reveal varying efficacy of CDK4/6 inhibitors in HR+/HER2- aBC, supporting personalized treatment choices.
Read More
Lancet Study: Darolutamide Shows No Clinical Benefit in AR+ Triple-Negative Breast Cancer
Yvette C. Terrie
Triple-Negative Breast Cancer
|
May 6, 2025
Darolutamide did not meet the clinical benefit endpoint in AR-positive TNBC, per findings from the phase II START trial.
Read More
Study Shows No Clinical Benefit Observed With Atezolizumab as Adjunctive Therapy for Triple Negative Breast Cancer
Yvette C. Terrie
Triple-Negative Breast Cancer
|
April 8, 2025
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Read More
Study Shows That Black Patients With Metastatic Breast Cancer Tend to Experience Higher Mortality Rates Than White Patients
Yvette C. Terrie
Breast Cancer News
|
April 6, 2025
Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.
Read More
Interim SERENA-6 Data: Camizestrant Significantly Improves PFS in First-Line HR+/HER2- Advanced Breast Cancer With ESR1 Mutations
Yvette C. Terrie
HR Breast Cancer
|
April 4, 2025
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
Read More